Acarbose: oral antidiabetes drug with additional cardiovascular benefits

References

• Wallander M, Bartnik M, Efendic S et al. β cell dysfunction in patients with acute myocardial infarction but without previously known Type 2 diabetes: a report from the GAMI study. Diabetologia48(11), 2229–2235 (2005).
   Google Scholar
• Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke25(5), 951–957 (1994).
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care26(3), 688–696 (2003).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fischer S, Julius U et al.; the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11 years follow-up. Diabetologia39(12), 1577–1583 (1996).
   Google Scholar
• Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med.164(19), 2090–2095 (2004).
   PubMed Web of Science ®Google Scholar
• Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol.34(1), 146–154 (1999).
   PubMed Web of Science ®Google Scholar
• Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in Type 2 diabetic patients. Circulation112(2), 179–184 (2005).
   PubMed Web of Science ®Google Scholar
• Yajnik CS, Joglekar CV, Lubree HG et al. Adiposity, inflammation and hyperglycaemia in rural and urban Indian men: Coronary Risk of Insulin Sensitivity in Indian Subjects (CRISIS) Study. Diabetologia51(1), 39–46 (2007).
   Google Scholar
• Yudkin JS. Insulin resistance and the metabolic syndrome – or the pitfalls of epidemiology. Diabetologia50(8), 1576–1586 (2007).
   PubMedGoogle Scholar
• Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA295(14), 1681–1687 (2006).
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Szoke E, Meyer C et al. Mechanisms for abnormal postprandial glucose metabolism in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab.290(1), E67–E77 (2006).
   PubMed Web of Science ®Google Scholar
• Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care22(2), 233–240 (1999).
   PubMed Web of Science ®Google Scholar
• Hanefeld M. Normnahe postprandiale Hyperglykämie – eine essenzielle Komponente guter Diabeteskontrolle und Prävention kardiovaskulärer Erkrankungen. Diabetologie2, 62–69 (2007).
   Google Scholar
• Salsburg DS. The UGDP study. JAMA218(11), 1704–1705 (1971).
   Google Scholar
• Puls W. Pharmacology of glucosidase inhibitors. Oral Antidiabetics119, 497–525 (1996).
   Google Scholar
• Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften64, 536–537 (1977).
   PubMed Web of Science ®Google Scholar
• Schmidt DD, Frommer W, Junge B et al. α-glucosidase inhibitors. New complex oligosaccharides of microbial origin.Naturwissenschaften64, 535–536 (1977).
   PubMed Web of Science ®Google Scholar
• Krause HP, Ahr HJ. Pharmacokinetics and metabolism of glucosidase inhibitors. In: Handbook of Experimental Pharmacology: Oral Antidiabetics.119. Kuhlmann J, Puls W (Eds). Springer, Berlin, Germany (1996).
   Google Scholar
• Junge B, Matzke M, Stoltefuss J. Chemistry and structure-activity relationships of glucosidase inhibitors. In:Handbook of Experimental Pharmacology: Oral Antidiabetics.119. Kuhlmann J, Puls W (Eds). Springer, Berlin, Germany (1996).
   Google Scholar
• Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism. Br. J. Clin. Pharmacol.30, 391–396 (1990).
   Google Scholar
• Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by α-glucosidase inhibitors. In: Pharmacology of Diabetes. Mogensen CE, Standl E (Eds). De Gruyter, Berlin, Germany93–112 (1991).
   Google Scholar
• Qualmann C, Nauck MA, Hoist JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (17–36 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using a-glucosidase inhibition (acarbose). Scand. J. Gastroenterol.30, 892–896 (1995).
   PubMed Web of Science ®Google Scholar
• Meneilly G, Ryan EA, Radziuk J et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care23, 1162–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Hillebrand I, Boehme K, Frank G, Fink H, Berchtold P. The effects of the α-glucosidase inhibitor BAY g 5421 (acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose–time–response relationships in man. Res. Exp. Med. (Berl.)175(1), 87–94 (1979).
   Google Scholar
• Hanefeld M, Haffner SM, Menschikowski M et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res. Clin. Pract.55(3), 221–227 (2002).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Leiter LA et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care19(11), 1190–1193 (1996).
   PubMed Web of Science ®Google Scholar
• Laube H, Linn T, Heyen P. The effects of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp. Clin. Endocrinol. Diabetes106, 231–233 (1998).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet359(9323), 2072–2077 (2002).
   PubMed Web of Science ®Google Scholar
• Göke B, Fuder H, Wieckhorst G et al. Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion56(6), 493–501 (1995).
   PubMed Web of Science ®Google Scholar
• Holman RR, Cull CA, Turner RC. A randomised double-blind trial of acarbose in Type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care22(6), 960–964 (1999).
   PubMed Web of Science ®Google Scholar
• Wolever TMS, Chiasson JL, Josse R et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int. J. Obes. Relat. Metab. Disord.21(9), 756–763 (1997).
   PubMed Web of Science ®Google Scholar
• Lindström J, Tuomilehto J, Spengler M. Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acarbose Study Group. Diabet. Med.17(1), 20–25 (2000).
   Google Scholar
• Rosenbaum P, Peres RB, Zanella MT, Ferreira SR. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure. Braz. J. Med. Biol. Res.35, 877–884 (2002).
   Google Scholar
• Rosenthal JH, Mauersberger H. Effects on blood pressure of the α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and Type 2 diabetes mellitus. Clin. Drug Invest.22(10), 695–701 (2002).
   Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA23;290(4), 486–494 (2003).
   Google Scholar
• Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J.25(1), 10–16 (2004).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care14(8), 732–737 (1991).
   PubMed Web of Science ®Google Scholar
• Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of α-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur. J. Clin. Invest.24(Suppl. 3), 45–49 (1994).
   PubMedGoogle Scholar
• Inoue I, Shinoda Y, Nakano T et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism55(7), 946–952 (2006).
   PubMed Web of Science ®Google Scholar
• Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia45(4), 461–475 (2002).
   PubMed Web of Science ®Google Scholar
• Rudofsky G, Reismann P, Schiekofer S et al. Reduction of postprandial hyperglycemia in patients with Type 2 diabetes reduces NF-B activation in PBMCs. Horm. Met. Res.36, 630–638 (2004).
   PubMed Web of Science ®Google Scholar
• Tschoepe D. Decreased fibrinogen by treatment with the α-glucosidase inhibitor acarbose. Diabetes53(Suppl. 2), A189 (2004).
   Google Scholar
• Schäfer A, Widder J, Eigenthaler M, Bischoff H, Ertl G, Bauersachs J. Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose. Thromb. Haemost.92(1), 97–103 (2004).
   PubMedGoogle Scholar
• Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia39(4), 469–473 (1996).
   PubMed Web of Science ®Google Scholar
• Wang X, Lu J, Pan C. Comparison of serum C-reactive protein level in different glucose tolerance subjects and the change in serum CRP level in IGT subjects with acarbose. EASD 2003Endocrinol. Metab.19, 254–256 (2003).
   Google Scholar
• Koehler C, Schaper F, Bergmann S, Hanefeld M. Effect of acarbose on subclinical inflammation and immune-response in early Type 2 diabetes and risk of atherosclerosis (AI(I)DA) study. Diab. Vasc. Dis. Res.4, S152 (2007).
   Google Scholar
• Lebovitz HE. α-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev6, 132–145 (1998).
   Google Scholar
• Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of Type I diabetes. Diabetes Care20(3), 248–253 (1997).
   PubMed Web of Science ®Google Scholar
• Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol.35(1), 34–40 (1998).
   PubMed Web of Science ®Google Scholar
• van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. α-glucosidase inhibitors for patients with Type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care28(1), 154–163 (2005).
   PubMed Web of Science ®Google Scholar
• Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with Type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin. Drug Investig.27(6), 397–405 (2007).
   PubMed Web of Science ®Google Scholar
• Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 Diabetes: data from 5-year surveillance study. Diabetes Res. Clin. Pract.2, 193–204 (2001).
   Google Scholar
• Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med.121(12), 928–935 (1994).
   PubMed Web of Science ®Google Scholar
• Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur. Heart J.25(22), 1990–1997 (2004).
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tango T. Efficacy of lifestyle education to prevent Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care28(11), 2780–2786 (2005).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346(6), 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent Type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia49(2), 289–297 (2006).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet368(9541), 1096–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA298(10), 1189–1195(2007).
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab.92(4), 1305–1310 (2007).
   PubMed Web of Science ®Google Scholar
• Yang WY, Lin L, Qi. The preventive affect of acarbose and metformin on the IGT population from diabetes mellitus: a 3-year multicentre prospective trial. Chin. J. Endocrinol. Metab.17, 131–136 (2001).
   Google Scholar
• Wascher TC, Schmoelzer I, Wiegratz A et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur. J. Clin. Invest.35(9), 551–557 (2005).
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Chiasson JL, Koehler C et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke35(5), 1073–1078 (2004).
   PubMed Web of Science ®Google Scholar
• Ludwig M, Kraft K, Rucker W, Huther AM. Diagnosis of very early arteriosclerotic vascular wall changes using duplex sonography. Klin. Wochenschr.67, 442–446 (1989).
   Google Scholar
• Handa N, Matsumoto M, Maeda H et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke21, 1567–1572 (1990).
   PubMed Web of Science ®Google Scholar
• May C. Efficacy and tolerability of step wise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM) treated with sulfonylureas. Diabetes Stoffwechsel4, 3–7 (1995).
   Google Scholar